CD8+ T cell – Page 4 – Communicable Diseases Research

CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives

Review

Published on 2022-04-012023-07-08
Journal: Frontiers in Immunology [Category] COVID19(2023년),

Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals

이전에 COVID-19에 감염된 개인과 감염되지 않은 개인에서 mRNA 백신의 1차 및 2차 접종에 대한 면역 반응을 평가하기 위한 상업용 인터페론-감마 방출 분석

Article

Published on 2022-04-012022-09-12
Journal: Diagnostic microbiology and infectious disease [Category] COVID19(2023년), MERS, SARS, 진단,

In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape

새로운 SARS-CoV-2 계통에서 돌연변이 에피토프의 실리코 분석은 전 세계적으로 향상된 CD8+ T 세포 반응성과 면역 반응 탈출의 징후를 시사합니다

Article

Published on 2022-04-012022-09-11
Journal: Infection, genetics and evolution : journal of mol [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료법,

[키워드] Analysis antibody B.1.1.7 B.1.351 binding Binding prediction Brazil CD8+ CD8+ T cell CD8+ T cell response CD8+ T cells change class Class I HLA conserved country Coverage COVID-19 E484K epitope Epitopes evade Evidence exhibiting expected fraction highlight HLA allele HLA alleles HLA binding immune response immunogenic in silico individual investigated Lineage lineages mutant Mutation N501Y new SARS-CoV-2 P.1 P.2 peptide peptides predicted provided reactivity reference sequence respond response SARS-CoV-2 SARS-CoV-2 variants silico predictions South Africa spike T cell T cell epitopes T cells TCR Transmissibility variant variants variants of concern Viral load
[DOI] 10.1016/j.meegid.2022.105236 PMC 바로가기 [Article Type] Article

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

Research

Published on 2022-03-142022-10-05
Journal: Nature Immunology [Category] 치료제,

Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine

비활성화된 COVID-19 백신으로 예방접종 후 동적 SARS-CoV-2 특이적 B 세포 및 T 세포 반응

Article

Published on 2022-03-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adaptive immune response Adaptive responses affected age analysed B cell B cells booster dose CD4 CD4+ T cell CD8 CD8+ T cell Cell cells cellular response circulating Cohort CoronaVac coronavirus COVID-19 COVID-19 vaccine declined dose doses dynamic effector memory elicited first dose geometric mean geometric mean titre GMT Healthcare professional Human humoral IgA response IgG response IgG responses immune responses immunization implication inactivated Inactivated virus vaccine magnitude memory memory B memory B cell memory B cells memory CD4+ T cells memory CD8+ T cells naïve neutralization neutralizing activities offer peripheral B cells prospective cohort reached Receptor binding domain robust SARS-CoV-2 SARS-CoV-2 spike-specific SARS-CoV-2-specific antibodies SARS-CoV-2-specific B-cell serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies subset sustained T cell T cell responses T cells T-cell Response terminally differentiated terminally differentiated effector memory cells timepoints vaccination Vaccine virus
[DOI] 10.1016/j.cmi.2021.10.006 PMC 바로가기 [Article Type] Article

High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19

Observational Study

Published on 2022-03-012022-10-05
Journal: Scandinavian journal of immunology [Category] SARS, 임상,

Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+monocytes and memory CD8+T cells involved in severe COVID-19

Research

Published on 2022-02-172022-10-31
Journal: Genome Medicine [Category] COVID-19, MERS,

[키워드] ABO airways alteration association calculate CCR1 CD8+ T cell CD8+T cell Cell cell types Cell-mediated immunity cells chemotaxis collected contribute Control COVID-19 COVID-19 infection COVID-19 pandemic CXCR6 cytokine detrimental disease severity dysregulated immune response Effect effective vaccine elevated epithelial cell expressed expressed gene expression facilitate Factor feature functional Genes Genetic genetic architecture genetic determinant GWAS GWAS summary statistics healthy control higher risk Host host genetics IFITM1 Immune cell immune cells immune response Immunity immunological increase in independent Inflammatory Inflammatory cytokines inflammatory storm Interaction involved lung tissues memory Migration Mild moderate mononuclear cell notable Patient PBMC Peripheral blood progression proliferation provide recruitment Result reveal risk S100A12 S100A8 S100A9 scRNA-seq dataset sequencing data severe COVID-19 Severe infection Severe patient severe patients severity of COVID-19 significantly single-cell single-cell sequencing subpopulation subset subtype supplementary material Symptom T cell understanding up-regulated
[DOI] 10.1186/s13073-022-01021-1 PMC 바로가기 [Article Type] Research

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses

Research

Published on 2022-02-012022-10-05
Journal: Nature Immunology [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술,

Homologous and Heterologous Covid-19 Booster Vaccinations

Original Article

Published on 2022-01-262022-11-01
Journal: The New England Journal of Medicine [Category] COVID-19, Fulltext, SARS,

[키워드] acute respiratory syndrome Ad26.COV2.S Ad26.COV2.S vaccine antibody assigned binding BNT162b2 booster Booster vaccine Breakthrough infection CD8+ T cell CD8+ T-cell clinical trial combinations conducted coronavirus coronavirus disease dose effective Emergency use authorization enrolled had no headache Heterologous homologous humoral immunogenicity immunogenic Infection injection Injection-site pain malaise Moderna mRNA vaccine mRNA-1273 myalgia Neutralizing antibody titer Neutralizing titer Open-label participant Pfizer–BioNTech primary end point pseudovirus reactogenicity receive recipient recipients regimen reported Result safety profile SARS-CoV-2 SARS-CoV-2 D614G T-cell Response the United State The United States Trial Vaccine virus particles
[DOI] 10.1056/NEJMoa2116414 PMC 바로가기 [Article Type] Original Article

Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination

mRNA 백신 접종 후 치명적인 코로나19 감염에 대한 중간 정도의 면역 반응

Immunology

Published on 2022-01-252022-09-11
Journal: Frontiers in Immunology [Category] 변종, 진단, 치료기술, 치료법, 치료제,

[키워드] Alpha Alpha variant Alpha VOC analyzed anti-SARS-CoV-2 vaccination Antibody titers antigenic target Breakthrough infection CD4+ CD4+ T-cell CD8+ T cell CD8+ T cells cellular Cohort COVID-19 COVID-19 disease detectable disease manifestation disease onset Disease progression donors Endemic fatal COVID-19 had no humoral immune response Humoral immunity Inclusion indicate individual moderate mounted mRNA mRNA-based Neutralizing antibodies Neutralizing antibody titer Patient reduced response resulting robust S-protein SARS-CoV-2 SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants T cells T-cell Response Trigger uninfected Vaccination strategy Vaccine vaccine breakthrough infection variant VoC VOCs wild type
[DOI] 10.3389/fimmu.2022.816220 PMC 바로가기 [Article Type] Immunology